Purchase this article with an account.
So Goto, Yasushi Ikuno, Yukari Joh, Fumi Gomi, Kaori Sayanagi, Kohji Nishida; One Year Follow-up Data Of Simple Hemorrhage In Highly Myopic Eyes In Comparison With Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3611.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Simple hemorrhage (SH) is often seen in the highly myopic eyes. The long-term follow-up data of this pathological condition is quite poorly investigated. Also myopic choroidal neovascularization (mCNV) became treatable with anti-vascular endothelial growth factor (VEGF). We investigated the 1-year prognosis of SH, and compared with that of mCNV.
Study eyes were 50 highly myopic eyes of 46 patinets (22 males and 24 females), which were diagnosed as SH or mCNV from July, 2004 to February, 2010 by fluorescein angiography. The patient was younger than 60 years old and the minimum follow-up was 12 months. We retrospectively investigated best-corrected visual acuity (BCVA) in SH group and mCNV group and compared them. SH was followed-up with observation, while all of mCNV eyes were treated with intravitreal bevacizumab.
There were 20 eyes of 17 patients in SH group and 30 eyes of 29 patients in mCNV group. The mean age was 41.1+/-1.6 years old. The mean refractive error was -13.0 +/- 3.4 diopter, and mean axial length was 29.65+/-1.39 mm. SH group was significantly younger (34.8 vs 45.8 years, P<0.001). In both groups, the BCVA at 12 months was significantly improved (P<0.001 and P<0.01, respectively). The age-adjusted baseline BCVA by analysis of covariance (ANCOVA) was 0.35 in SH group and 0.36 in mCNV group, which were at similar level (P=0.93). BCVA at 3 months was 0.15 and 0.23 (P=0.35), 0.11 and 0.17 at 6 months (P=0.41), and 0.05 and 0.21 at 12 months (P=0.07), which was of borderline significance. The change in vision at 12 months was 0.30 in SH and 0.12 in mCNV, which was a significant difference (P<0.05).
VA is favorable in SH groups. Although mCNV was treated with anti-VEGF, SH still has better BCVA after 12 months than mCNV.
This PDF is available to Subscribers Only